@article{oai:ir.kagoshima-u.ac.jp:00005062,
 author = {UENO, Shinichi and 上野, 真一 and HIWATASHI, Kiyokazu and 樋渡, 清司 and SAKODA, Masahiko and 迫田, 雅彦 and IINO, Satoshi and 飯野, 聡 and KURAHARA, Hiroshi and 蔵原, 弘 and MINAMI, Koji and 南, 幸次 and ANDO, Kei and 安藤, 慶 and MAEMURA, Kosei and 前村, 公成 and MATAKI, Yukou and 又木, 雄弘 and MATSUMOTO, Masataka and 松本, 正隆 and OWAKI, Tetsuhiro and 大脇, 哲弘 and KITAZONO, Masaki and 北薗, 正樹 and ISHIGAMI, Sumiya and 石神, 純也 and SHINCHI, Hiroyuki and 新地, 洋之 and NATSUGOE, Shoji and 夏越, 祥次},
 issue = {3},
 journal = {鹿児島大学医学雑誌, Medical journal of Kagoshima University},
 month = {Jan},
 note = {Background: High mobility group box-1 (HMGB1) induces the release of proinflammatory cytokines and chemokines
as a late-acting mediator of inflammation. Hepatocellular carcinoma (HCC) is a typical inflammation-related cancer,
however, little is known about the relationship between HCC and HMGB1 and its receptor RAGE (receptor for advanced
glycation end products). We studied the clinicopathological relevance of the expression level of HMGB1 and the effect of
HMGB1 expression on the characteristics of HCC.
Methods: Samples from the 36 HCC patients including 7 with positive hepatitis B surface antigen and 21 with hepatitis
C antibody were studied. Twenty-four patients had chronic active hepatitis and 4 had liver cirrhosis. The expression of
HMGB1 was assessed in paired cancerous and noncancerous tissues with HCC, using reverse-transcription polymerase
chain reaction (RT-PCR), and Western blotting. Quantitative RT-PCR data were analyzed relation to clinicopathological
features. As a control study, 7 normal liver samples were collected from patients other than HCC. Results: The expression of HMGB1 mRNA was lower in normal liver than in noncancerous tissue and the highest
in HCC, although the differences were not significant. Furthermore, in HCC, it was high in well- and moderately
differentiated tumors but declined as tumors dedifferentiated to poorly differentiated HCC (p=0.033). The expression
level was inversely correlated with tumor recurrence (p=0.036). No significant correlations were observed between the
expression levels and well-known prognostic factors of HCC (e.g. portal invasion and intrahepatic metastasis).
Conclusion: In HCC, HMGB1 expression level correlated inversely with the patient’s prognosis. The HMGB1 mRNA
expression level is similar to the level we reported previously in a study on the clinicopathological relevance of the level of
RAGE in HCC. RAGE-HMGB1 interaction in HCC might work in the early stage of tumorigenesis more than in the stage of
cancer development.},
 pages = {27--35},
 title = {Significance of High Mobility Group Box-1 (HMGB1) Expression in Hepatocellular Carcinoma},
 volume = {62},
 year = {2011}
}